NxStage Medical today announced that at a special meeting of stockholders held today, the Company’s stockholders voted to adopt the previously announced Agreement and Plan of Merger, dated August 7, 2017.
| |
| [27-October-2017] |
| LAWRENCE, Mass., Oct. 27, 2017 /PRNewswire/ -- NxStage Medical, Inc., a leading medical technology company focused on advancing renal care, today announced that at a special meeting of stockholders held today, the Company’s stockholders voted to adopt the previously announced Agreement and Plan of Merger, dated August 7, 2017 (the “Merger Agreement”), with Fresenius Medical Care Holdings, Inc. (“Fresenius”), whereby Fresenius will acquire NxStage through a wholly-owned subsidiary of Fresenius. The approval of the Merger Agreement fulfills an important condition for the full acquisition of NxStage Medical, Inc. Approximately 94% of the vote cast at today’s special meeting of stockholders voted in favor of the adoption of the Merger Agreement. This represents approximately 72% of NxStage’s total outstanding shares of common stock as of the September 20, 2017 record date and constitutes a majority of the outstanding shares of NxStage common stock entitled to vote at the special meeting, as required to adopt the Merger Agreement. Upon completion of the merger, NxStage stockholders will be entitled to received $30.00 in cash, without interest, for each share of NxStage’s common stock that such stockholder owns. The merger, which is expected to be completed in 2018, remains subject to additional customary closing conditions, including regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act in the U.S. About NxStage Medical Forward-Looking Statements
Media contact:
View original content with multimedia:http://www.prnewswire.com/news-releases/nxstage-announces-stockholder-approval-of-merger-agreement-with-fresenius-medical-care-300544857.html SOURCE NxStage Medical, Inc. | ||
Company Codes: NASDAQ-NMS:NXTM |
